Antibe Therapeutics (ATE) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock ATE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period How a mom of two who ‘ate her emotions’ lost over 120 pounds in under a yearAugust 3, 2024 | nypost.comNCanadian Investment Regulatory Organization Trading Halt - ATEApril 9, 2024 | finance.yahoo.comAntibe Announces Unfavorable Decision in Arbitration With Nuance PharmaMarch 4, 2024 | finance.yahoo.comAntibe Therapeutics (TSE:ATE) Share Price Passes Above 50-Day Moving Average of $0.92February 9, 2024 | marketbeat.comAntibe Extends Early Warrant Exercise Incentive ProgramFebruary 1, 2024 | finance.yahoo.comAntibe Therapeutics Inc ATEDecember 31, 2023 | morningstar.comMAntibe Announces Early Warrant Exercise Incentive ProgramDecember 29, 2023 | finance.yahoo.comAntibe Reports Q2 2024 Interim Financial and Operating ResultsNovember 13, 2023 | finance.yahoo.comAntibe Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (ATE)November 8, 2023 | theglobeandmail.comHercules at 52-Week High on Barrick HookupNovember 6, 2023 | baystreet.caAntibe at 52-Week High on NewsNovember 1, 2023 | baystreet.caAntibe Completes First Clinical Study of Otenaproxesul’s New FormulationNovember 1, 2023 | finance.yahoo.comAntibe Initiates First Clinical Study of Otenaproxesul's New FormulationOctober 18, 2023 | benzinga.comStocks in play: Antibe Therapeutics Inc.September 28, 2023 | ca.finance.yahoo.comAntibe Receives Approval to Initiate PK/PD Study of OtenaproxesulSeptember 28, 2023 | finance.yahoo.comAntibe Therapeutics Inc. (ATE)September 6, 2023 | investing.comToronto Stock Exchange, Antibe Therapeutics Inc., View From The C-SuiteAugust 21, 2023 | finance.yahoo.comToronto Stock Exchange, Antibe Therapeutics Inc., View From The C-SuiteAugust 21, 2023 | finance.yahoo.comClosing Bell: Antibe Therapeutics Inc down on Wednesday (ATE)August 17, 2023 | theglobeandmail.comAntibe Therapeutics Inc.'s (TSE:ATE) Path To ProfitabilityJune 30, 2023 | finance.yahoo.comLast Week of June Looks EventfulJune 23, 2023 | baystreet.caBest Times To Visit AntibesJune 16, 2023 | travel.usnews.comClosing Bell: Antibe Therapeutics Inc up on Monday (ATE)June 12, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Friday (ATE)June 3, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Thursday (ATE)May 19, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc flat on Thursday (ATE)April 28, 2023 | theglobeandmail.comAntibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials SummitApril 25, 2023 | finance.yahoo.comClosing Bell: Antibe Therapeutics Inc up on Tuesday (ATE)April 18, 2023 | theglobeandmail.comAntibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 18, 2023 | finance.yahoo.comClosing Bell: Antibe Therapeutics Inc down on Monday (ATE)April 17, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc flat on Friday (ATE)April 14, 2023 | theglobeandmail.comAntibe Provides April 2023 Corporate UpdateApril 11, 2023 | finance.yahoo.comClosing Bell: Antibe Therapeutics Inc flat on Monday (ATE)April 11, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Thursday (ATE)April 7, 2023 | theglobeandmail.comAntibe Reports Q3 2023 Interim Financial and Operating ResultsFebruary 15, 2023 | finance.yahoo.comAntibe Therapeutics: Top 25 Undervalued Toronto Stock Exchange Stocks (ATE)February 5, 2023 | theglobeandmail.comAntibe Reports Q2 2023 Interim Financial and Operating ResultsNovember 15, 2022 | finance.yahoo.comAntibe Closes Previously Announced Strategic Sale of Citagenix SubsidiaryNovember 2, 2022 | finance.yahoo.comAntibe Therapeutics: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (ATE)November 1, 2022 | theglobeandmail.comAntibe Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSE (ATE)September 15, 2022 | theglobeandmail.comAntibe Therapeutics: Stocks trading at Less Than Cash Value on (ATE)September 12, 2022 | theglobeandmail.comATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul…September 7, 2022 | finance.yahoo.comAntibe Therapeutics: Bottom 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (ATE)August 18, 2022 | theglobeandmail.comAntibe Therapeutics Inc stock advanced on Friday.August 2, 2022 | theglobeandmail.comAntibe Therapeutics Announces Amendment to Warrant TermsJune 15, 2022 | nz.finance.yahoo.comAntibe Therapeutics Inc. (ATE.TO)June 3, 2022 | finance.yahoo.comAntibe Therapeutics Announces Strategic Sale of Citagenix SubsidiaryMay 2, 2022 | finance.yahoo.comATE.TO: First Human PK/PD Studies Underway in Otenaproxesul’s Post-Operative Pain Program…February 16, 2022 | msn.comATE.TO: First Human PK/PD Studies Underway in Otenaproxesul’s Post-Operative Pain Program…February 16, 2022 | finance.yahoo.comAntibe Therapeutics Inc. (TSE:ATE) Given Consensus Rating of "Buy" by AnalystsJanuary 2, 2022 | marketbeat.com Get Antibe Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter. Email Address ATE Media Mentions By Week ATE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATE News Sentiment▼0.000.42▲Average Medical News Sentiment ATE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATE Articles This Week▼00▲ATE Articles Average Week Get Antibe Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Helix BioPharma News Microbix Biosystems News Devonian Health Group News Hemostemix News Sirona Biochem News Innovotech News Quest PharmaTech News Kane Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:ATE) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
